By providing time-saving options for treatment, Roche may be able to secure market share for its innovator biologics if savings in terms of chair time for patients are able to offset the eventual price discounts made available by biosimilar developers for their products.
Roche’s Genentech has announced that a phase 3 study of a proposed fixed-dose combination of its pertuzumab (Perjeta) and trastuzumab (Herceptin) has met its primary end point of trough serum concentration of pertuzumab during cycle 7.
The FeDeriCa study, an international, multicenter, 2-arm, randomized open-label study is designed to evaluate the safety and efficacy of a subcutaneous injection of the antibody combination together with chemotherapy in patients with HER2-positive early breast cancer in the neoadjuvant and adjuvant settings. In total, 500 patients were randomized to receive either pertuzumab and trastuzumab intravenously together with chemotherapy, or to receive the subcutaneous combination plus chemotherapy.
According to Genentech, in addition to meeting the primary end point, the safety profile for the combination therapy was consistent with the known safety profiles of the 2 drugs when administered intravenously.
The combination offers the time-saving benefit of an approximately 8-minute loading dose followed by 5-minute maintenance doses, compared with 150-minute loading doses and 60- to 150-minute maintenance doses of the intravenous therapies.
“With this single injection under the skin, people with HER2-positive breast cancer receiving Perjeta and Herceptin can have a faster treatment option,” said Sandra Horning, MD, chief medical officer and head of global product development at Roche. “Our medicines have helped millions of people living with HER2-positive breast cancer and this latest development is particularly exciting as, for the first time, we have combined two therapeutic antibodies as a single subcutaneous formulation.”
The proposed combination is the latest subcutaneous option developed by Roche in conjunction with Halozyme Therapeutics; in 2006, Roche entered into an agreement with Halozyme to develop subcutaneous versions of several of its top-selling biologics, including rituximab (MabThera) and trastuzumab (Herceptin), both of which now have approved subcutaneous options in multiple regulatory territories.
Halozyme’s approach is based on a proprietary recombinant human hyaluronidase PH20, an enzyme that temporarily degrades hyaluronan in order to aid in the dispersion and absorption of other injected therapeutic drugs.
Such subcutaneously administered options for Roche’s innovator products are emerging as biosimilar competition begins to take hold in earnest in the European marketplace, where multiple biosimilars of intravenously infused trastuzumab and rituximab have launched. In the United States, just one intravenous trastuzumab biosimilar—Amgen’s Kanjinti—is commercially available, but additional approved agents are expected to enter the marketplace in the coming months. While no pertuzumab biosimilars are on the immediate horizon, by providing time-saving options for treatment, Roche may be able to secure market share for its innovator biologics if savings in terms of chair time for patients are able to offset the eventual price discounts made available by biosimilar developers for their products.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.